Shanghai Pharmaceuticals Holding (601607.SH): Clevidipine Emulsion Injection Approved for Production
Shanghai Pharmaceuticals Holding (601607.SH) announced that recently, its subsidiary Shanghai SPH First Biochemical Pharmaceutical Co., Ltd. received the Drug Registration Certificate issued by the National Medical Products Administration for Clevidipine Emulsion Injection, and the drug has been approved for production. The drug is mainly used for the treatment of hypertension in patients for whom oral therapy is not suitable or expected to be ineffective.
Shanghai Pharmaceuticals Holding (601607.SH) announced that recently, its subsidiary Shanghai SPH First Biochemical Pharmaceutical Co., Ltd. received a Drug Registration Certificate issued by the National Medical Products Administration for Clevidipine Emulsion Injection, and the drug was approved for production. The drug is mainly used for the treatment of hypertension in patients for whom oral therapy is not suitable or expected to be ineffective.
Related Articles
CGN NEW ENERGY (01811) repurchased 740,000 shares for HK$1.5805 million on October 9.
COURAGE INV (01145) repurchased 360,000 shares for HK$42,000 on October 9.
FOUNDER HOLD (00418) repurchased 4,000 shares for HK$2,560 on October 9.
CGN NEW ENERGY (01811) repurchased 740,000 shares for HK$1.5805 million on October 9.
COURAGE INV (01145) repurchased 360,000 shares for HK$42,000 on October 9.
FOUNDER HOLD (00418) repurchased 4,000 shares for HK$2,560 on October 9.
